Pharma BD Deal Intelligence
A $950M cash-and-contingent buy that Mylan wrote down twice within two years—$61.6M in 2017 and $72M more across 2018—before the topicals business vanished into Viatris' segment reporting with no standalone results ever disclosed again.
Mylan's $1B dermatology bet took two confirmed impairment hits within two years, and the assets disappeared into segment-level reporting before being absorbed into Viatris with no standalone accounting ever surfacing again.
Full analysis, sources & comparables →Mylan snapped up the Renaissance dermatology business for ~$1B, with FiercePharma noting the deal complements the pending Meda dermatology assets and signals a…
Pharmaceutical Technology framed the transaction as Mylan adding ~25 marketed topicals plus a ~25-product pipeline and a topicals CDMO, characterizing it as a…
CEO Heather Bresch: 'By bringing together the Renaissance topicals business with Mylan's existing assets and the pending addition of Meda... we will become a…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Mylan acquired the non-sterile topicals-focused specialty and generics business of Renaissance Acquisition Holdings for $950M cash at closing plus contingent payments up to $50M (~$1B total). Acquired ~25 branded/generic topical products, an active pipeline of ~25 products, U.S. dermatology sales infrastructure, and integrated manufacturing. Closed June 15, 2016. ~$370M in 2015 revenues.
Mylan's $1B dermatology bet took two confirmed impairment hits within two years, and the assets disappeared into segment-level reporting before being absorbed into Viatris with no standalone accounting ever surfacing again.
Assessment window: 5yr post-close.
$7.8B US dermatologicals spend (2019, nearest available; 2015-16 era similar order-of-magnitude)
Topical dermatology covers a broad set of skin conditions — acne, psoriasis, atopic dermatitis, rosacea, fungal/bacterial infections — addressed via creams, ointments, gels, and foams prescribed primarily by dermatologists and primary care. The category combines branded specialty products with high-volume generics, where formulation expertise and manufacturing scale are key competitive moats.
The US topical dermatology market in 2016 was a fragmented, scale-driven category with branded specialty leaders and generics consolidators competing on portfolio breadth and manufacturing economics. Major branded competitors included Valeant (now Bausch Health) following its Medicis acquisition, Allergan's dermatology franchise, and Galderma. On the generics/specialty hybrid side, Sandoz (Novartis), Teva, Perrigo, and Taro Pharmaceutical were the principal scaled competitors. Mylan's strategic logic was twofold: (1) bolt the Renaissance topicals onto the pending Meda dermatology portfolio (acquired 2016) to create a top-tier US dermatology franchise; (2) acquire integrated topicals manufacturing and a CDMO to lock in cost advantage as new topical generics launched. Renaissance brought ~25 marketed branded/generic topicals plus a ~25-product pipeline, US dermatology sales infrastructure, and ~1,200 employees on $370M of 2015 revenue. CEO Heather Bresch positioned dermatology/topicals as a 'long-term focus area.' Importantly, this period also saw Pfizer-Anacor and Valeant-Salix dynamics reshaping topical pricing — Mylan's vertical-integration thesis (own the formulation + the manufacturing) was a defensible bet against pure-play generics commoditization. Source: http://newsroom.mylan.com/2016-06-15-Mylan-Completes-Acquisition-of-Renaissances-Leading-Topicals-Focused-Specialty-and-Generics-Business
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mylan N.V. / Renaissance Acquisition Holdings, LLC (topicals business) (this deal) | 2016 | $1.0B | 40 |
| Mylan N.V. / Meda AB | 2016 | $9.9B | 53 |
| Mylan N.V. / Upjohn Inc. (Pfizer) | 2019 | $12.0B | 44 |
| Mylan N.V. / Novartis AG (TOBI franchise) | 2018 | $463M | 38 |
| Mylan N.V. / Perrigo Company plc | 2015 | $26.0B | — |
| Ciba-Geigy AG / Sandoz AG | 1996 | $36.3B | 98 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
← Browse all deals · How we score deals
More: 2016 deals · Mylan N.V. deals · Dermatology deals